P009: Index of sustained Phe response and improvements in PKU clinical outcome assessments in patients receiving pegvaliase
Saved in:
| Main Authors: | Drew Levy, Naomi Schwartz, David Andrae, Sarah Rose, Hafiz Oko-osi, Ogün Sazova, Kristin Lindstrom |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-01-01
|
| Series: | Genetics in Medicine Open |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2949774425008921 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
P002: Improvements in blood phenylalanine and health-related quality of life outcomes among adults with PKU receiving pegvaliase in the OPAL study*
by: Markey McNutt, et al.
Published: (2025-01-01) -
P046: Occurrence of anaphylaxis in adult incident pegvaliase-treated PKU patients in a post-marketing safety analysis in the United States
by: Karly Louie, et al.
Published: (2025-01-01) -
Toxicity spectrum of pegvaliase: A pharmacovigilance analysis using the FAERS database
by: Luyao Xu, et al.
Published: (2025-06-01) -
Lessons learned from 5 years of pegvaliase in US clinics: A case series
by: Erin Cooney, et al.
Published: (2025-03-01) -
Evaluating adverse events of pegvaliase-pqpz in phenylketonuria treatment: A comprehensive safety assessment
by: Kai Yan, et al.
Published: (2025-04-01)